Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Pharmaceutical Co. Ltd.

Division of Roche
www.chugai-pharm.co.jp

Latest From Chugai Pharmaceutical Co. Ltd.

Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Chugai Ups Forecast On Star Performer Hemlibra

Roche affiliate substantially raises full-year forecast following double-digit sales and profit growth, mainly on the back of strength for hemophilia drug Hemlibra.

Japan Sales & Earnings

Roche Keeps Eye On The Science As Asia Innovation Emerges

Roche's main consideration when partnering is to "access great science" regardless of location. More of this is expected to come out of Asia, its global partnering head tells Scrip.

Asia Pacific Innovation

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals
See All

Company Information

UsernamePublicRestriction

Register